Safi Biotherapeutics Inc

We’re honored to have been awarded $3.5 million from the U.S. Department of Defense through the MTEC | Medical Technology Enterprise Consortium MPAI program to optimize enhanced cryo-storage capabilities unique to manufactured human red blood cells (mRBCs) and complete some important product development activities. ? With this prototyping award, we will optimize our cryo-preservation approach, expand our clinical strategy and trial design to include an acute bleeding indication, and refine our FDA IND-enabling pre-clinical studies. ? This work will be done in collaboration with the University of Colorado’s CU Center for COMBAT Research, Department of Emergency Medicine, and Department of Biochemistry and Molecular Genetics; and Emory University School of Medicine. ? Read more here: https://bit.ly/43aJRPq ? #RedBloodCells #Innovation #CellTherapy #LifeSciences

At Safi, we produce highly characterized, stem cell-derived human red blood cells (RBCs) for civilian and military transfusion needs. The civilian commercial opportunity includes chronic transfusion indications for anemias such as sickle cell disease (SCD), a rare disease that affects approximately 100K U.S. patients each year. About 10% of SCD patients require regular transfusions of RBCs, often monthly or more. Many of these patients tend to have rarer blood types and, due to the frequent transfusions, can also develop alloimmunizations that make it more challenging to locate appropriately matched RBC units. ? For #RareDiseaseDay, we want to reiterate our commitment to making economically viable mRBCs at industrial scale to augment the existing donor blood supply with a product appropriately tailored to meet the specific needs of these patients. ? #RBC #RedBloodCells #Innovation #CellTherapy #LifeSciences

We’re honored to have been awarded $3.5 million from the U.S. Department of Defense through the MTEC | Medical Technology Enterprise Consortium MPAI program to optimize enhanced cryo-storage capabilities unique to manufactured human red blood cells (mRBCs) and complete some important product development activities. ? With this prototyping award, we will optimize our cryo-preservation approach, expand our clinical strategy and trial design to include an acute bleeding indication, and refine our FDA IND-enabling pre-clinical studies. ? This work will be done in collaboration with the University of Colorado’s CU Center for COMBAT Research, Department of Emergency Medicine, and Department of Biochemistry and Molecular Genetics; and Emory University School of Medicine. ? Read more here: https://bit.ly/43aJRPq ? #RedBloodCells #Innovation #CellTherapy #LifeSciences

Today marks World Anemia Awareness Day! Anemia patients depend on chronic transfusions due to their lower red blood cell count, but donor banks often face shortages, particularly for patients at risk of alloimmunization, who require specific-typed blood units that are difficult to locate. ? At Safi, we are developing a manufactured human red blood cell product for anemia-related chronic transfusions to supplement these shortages and support the needs of patients who depend on them the most. ? #anemiathon2025 #RedBloodCells #Innovation #CellTherapy #LifeSciences

We're pleased to share that our CEO, Doug McConnell, was featured in SCRIP's "Scrip Asks…What Does 2025 Hold For Biopharma?" — where he shared his outlook for the year ahead in bio and views on the evolution of private sector and government partnerships. Have a read!?https://bit.ly/4apoUBS #Innovation #CellTherapy #LifeSciences #RedBloodCells

We’re pleased to announce a collaboration with Advanced Regenerative Manufacturing Institute (ARMI) | BioFabUSA to support large-scale development of our manufactured human red blood cells (mRBCs). ? This is a critical step toward manufacturing our mRBCs at a clinically meaningful scale and moving our product down the regulatory path toward an IND submission. ? We appreciate ARMI | BioFabUSA’s support of our efforts to address ongoing donor blood supply critical shortages in the U.S. and internationally. ? Read more here: https://bit.ly/4jOWaqB ? #RedBloodCells #Innovation #CellTherapy #LifeSciences

We're pleased to share that our CEO, Doug McConnell, was featured in SCRIP's "Scrip Asks…What Does 2025 Hold For Biopharma?" — where he shared his outlook for the year ahead in bio and views on the evolution of private sector and government partnerships. Have a read!?https://bit.ly/4apoUBS #Innovation #CellTherapy #LifeSciences #RedBloodCells

?? Exciting Innovation in Healthcare! I'm thrilled to highlight an incredible company, Safi Biotherapeutics Inc, led by my friend and CEO, Doug McConnell, that is pioneering the future of blood product manufacturing. Safi Therapeutics is partnering with the U.S. Department of Defense on a groundbreaking 5-year program to create on-demand blood products—a game-changer for both military and civilian healthcare. The company is tackling one of the toughest challenges in medical science: making high-quality, life-saving “lab-grown” blood products that can be produced quickly, consistently, and affordably. By combining cutting-edge expertise in cell therapy, bioprocessing, and manufacturing, Safi is working to make it easier and more efficient to produce blood products at scale. This could one day lead to faster access to blood when and where it’s needed most—potentially saving countless lives in the process. Read more about their groundbreaking work here: https://safi.bio/#about Exciting times ahead for Safi as they continue to push the boundaries of healthcare innovation. I’m proud to support their work and look forward to seeing where this journey takes them! #JPM #JPM2025 #HealthcareInnovation #CellTherapy #LifeSciences #Biotech #SafiBiotherapeutics #BloodProducts #MilitaryMedicine #Clarivate #CEO #Partnerships #Redbloodcells

Exciting to see my friend and incredible sickle cell advocate Jimi Olaghere speaking at the White House Cell and Gene Therapy forum! I was honored to be part of the Timmerman Traverse for Sickle Forward team with Jimi that submitted Mount Kilimanjaro this past September (led by Luke Timmerman Alan Anderson Ted W. Love, MD) to raise awareness and funding for Sickle Cell screening, care and research. Safi Biotherapeutics Inc is working hard to develop tailored, stem-cell derived manufactured RBCs for Sickle Cell patients that depend on chronic, often monthly or more, transfusions.

Special thanks to KLA Breakthrough Consulting for their great work on these submissions and designations!